• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Immix Biopharma Inc.

    3/25/26 5:27:43 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMMX alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on March 25, 2026

     

    Registration No. 333-          

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Immix Biopharma, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   45-4869378

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    11400 West Olympic Blvd., Suite 200

    Los Angeles, CA

      90064
    (Address of principal executive offices)   (Zip Code)

     

    AMENDED AND RESTATED

    IMMIX BIOPHARMA, INC.

    2021 OMNIBUS EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Ilya Rachman, MD PhD

    Chief Executive Officer

    11400 West Olympic Blvd., Suite 200

    Los Angeles, CA 90064

    (Name and address of agent for service)

     

    (310) 651-8041

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Gabriel Morris
    Chief Financial Officer

    Immix Biopharma, Inc.

     

    Leslie Marlow, Esq.
    Melissa Palat Murawsky, Esq.

    Blank Rome LLP

    11400 West Olympic Blvd., Suite 200
    Los Angeles, CA 90064

    Telephone: (310) 651-8041

     

    1271 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 885-5000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    Immix Biopharma, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”) to register an additional 4,024,556 shares (the “Shares”) of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”) issuable upon the grant, exercise or vesting of awards pursuant to the Registrant’s Amended and Restated 2021 Omnibus Equity Incentive Plan (the “Plan”) resulting from (i) an automatic increase pursuant to the “evergreen” provision in the Plan of 1,377,001 shares of Common Stock, such number of shares equal to 5% of the total number of shares of Common Stock outstanding as of December 31, 2024; and (ii) an automatic increase pursuant to the “evergreen” provision in the Plan of 2,647,555 shares of Common Stock, such number of shares equal to 5% of the total number of shares of Common Stock outstanding as of December 31, 2025. The Shares are in addition to and of the same class as the Common Stock for which the Registrant previously filed with the SEC: a Registration Statement on Form S-8 on July 22, 2024 (File No. 333-280929), a Registration Statement on Form S-8 on June 13, 2023 (File No. 333-272625) and a Registration Statement on Form S-8 on January 25, 2022 (File No. 333-262336) (collectively, the “Prior Registration Statements”). Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement.

     

    2
     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed with the Commission by the Company are incorporated by reference into this registration statement on Form S-8 (the “Registration Statement”) and are made a part hereof:

     

      (a) The Company’s Annual Report on Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026; and
         
      (b)

    The description of our common stock contained in the Registration Statement on Form 8-A, as filed with the SEC on December 13, 2021 (File No. 001-41159), including any amendments thereto or reports filed for the purposes of updating this description.

     

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of filing this Registration Statement and prior to such time as the Company files a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents, except for the documents, or portions thereof, that are “furnished” rather than filed with the SEC.

     

    Item 8. Exhibits

     

            Incorporated by Reference   Filed
    Exhibit No.   Description   Form   File No.   Exhibit   Filing Date  

    Herewith

    5.1*   Opinion of Blank Rome LLP                   X
    23.1*   Consent of Crowe LLP                   X
    23.2*   Consent of Blank Rome LLP (included in Exhibit 5.1)                   X
    24.1*   Power of Attorney (included on the signature page of this registration statement)                   X
    99.1   Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan***   8-K   001-41159   10.1   06/14/2024    
    99.2   Form of Stock Option Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) ***   S-8   333-280929   99.2   07/22/2024    
    99.3   Form of Restricted Stock Grant Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) ***   S-8   333-280929   99.3   07/22/2024    
    99.4   Form of Restricted Stock Unit Grant Agreement (Amended and Restated Immix Biopharma, Inc. 2021 Omnibus Equity Incentive Plan) ***   S-8   333-280929   99.4   07/22/2024    
    107*   Filing Fee Table                   X

     

    * Filed herewith.
    *** Indicates management contract or compensatory plan or arrangement.

     

    3
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Los Angeles, State of California on March 25, 2026.

     

      Immix Biopharma, Inc.
       
    Date: March 25, 2026 By: /s/ Ilya Rachman
      Name: Ilya Rachman
      Title:

    Chief Executive Officer

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the persons whose signature appears below constitute and appoint Ilya Rachman and Gabriel Morris, and each of them, with full power to act without the other, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement, and any and all amendments thereto (including post-effective amendments), and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Ilya Rachman   Chief Executive Officer, Chief Scientific Officer and Chairman   March 25, 2026
    Ilya Rachman   (Principal Executive Officer)    
             
    /s/ Gabriel Morris   Chief Financial Officer, President and Director   March 25, 2026
    Gabriel Morris   (Principal Financial and Accounting Officer)    
             
    /s/ Jason Hsu   Director   March 25, 2026
    Jason Hsu        
             
    /s/ Magda Marquet   Director   March 25, 2026
    Magda Marquet        
             
    /s/ Helen C. Adams   Director   March 25, 2026
    Helen C. Adams        
             
    /s/ Carey Ng   Director   March 25, 2026
    Carey Ng        
             
    /s/ Jane Buchan   Director   March 25, 2026
    Jane Buchan        
             
    /s/ Yekaterina Chudnovsky   Director   March 25, 2026
    Yekaterina Chudnovsky        
             
    /s/ Nancy Chang   Director   March 25, 2026
    Nancy Chang        

     

    4

     

    Get the next $IMMX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMMX

    DatePrice TargetRatingAnalyst
    3/25/2026$20.00Overweight
    Morgan Stanley
    3/9/2026$23.00Mkt Outperform
    Citizens
    2/9/2026$14.00Outperform
    Mizuho
    More analyst ratings

    $IMMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Immix Biopharma with a new price target

    Morgan Stanley initiated coverage of Immix Biopharma with a rating of Overweight and set a new price target of $20.00

    3/25/26 8:30:25 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Immix Biopharma with a new price target

    Mizuho initiated coverage of Immix Biopharma with a rating of Outperform and set a new price target of $14.00

    2/9/26 7:01:42 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Rachman Ilya M bought $4,976 worth of shares (746 units at $6.67), increasing direct ownership by 0.07% to 1,141,683 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:49:30 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Morris Gabriel S exercised 156,000 in-the-money shares at a strike of $0.80 and bought $5,067 worth of shares (770 units at $6.58), increasing direct ownership by 0.26% to 291,429 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:47:20 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rachman Ilya M bought $5,050 worth of shares (2,500 units at $2.02), increasing direct ownership by 0.22% to 1,140,937 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    9/17/25 5:20:33 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    SEC Filings

    View All

    SEC Form S-8 filed by Immix Biopharma Inc.

    S-8 - Immix Biopharma, Inc. (0001873835) (Filer)

    3/25/26 5:27:43 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immix Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Immix Biopharma, Inc. (0001873835) (Filer)

    3/25/26 5:23:48 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Immix Biopharma Inc.

    424B5 - Immix Biopharma, Inc. (0001873835) (Filer)

    3/25/26 5:21:45 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Chang Nancy T

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/11/25 8:00:32 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rachman Ilya M bought $4,976 worth of shares (746 units at $6.67), increasing direct ownership by 0.07% to 1,141,683 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:49:30 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Morris Gabriel S exercised 156,000 in-the-money shares at a strike of $0.80 and bought $5,067 worth of shares (770 units at $6.58), increasing direct ownership by 0.26% to 291,429 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:47:20 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immix Biopharma to Participate in Upcoming Investor Conferences

    LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host investor meetings at the following upcoming institutional investor conferences: Leerink Partners 2026 Global Healthcare Conference being held March 8-11, 2026 in Miami Beach, FL. The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami Beach, FL. Company management will host one-on-one meetings during the conferences. Interested investors should contact their Leerink or Citizens representative to request meetings. A link to access replays, when a

    3/3/26 8:45:00 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    – Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the

    12/9/25 5:45:00 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

    LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to certain investors in lieu of common stock, pre-funded warrants to purchase 490,196 shares of common stock at a price to the public of $5.09 per pre-funded warrant, which represents the per share public offering price for the common stock, less the $0.01 per share exercise price for each such pre-funded warrant. The gross proceeds to Immix from the offering, b

    12/7/25 6:20:00 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    Leadership Updates

    Live Leadership Updates

    View All

    Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

    Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi

    9/19/24 9:31:00 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

    LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

    6/10/24 8:30:00 AM ET
    $IMMX
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

    LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Sanchorawala is internationally recognized for her pioneering work in development of novel agents to treat AL Amyloidosis, including the establishment of daratumumab as the standard of care. "Therapeutic landscape of AL amyloidosis is evolving. There is a marked progress in survival of patients with AL amyloidosis. However, better and more effective therapies are needed for those relapsing after Daratumumab based treatments. I am

    1/4/24 9:34:00 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Immix Biopharma Inc.

    SC 13G - Immix Biopharma, Inc. (0001873835) (Subject)

    2/7/24 9:18:36 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Immix Biopharma Inc.

    SC 13D - Immix Biopharma, Inc. (0001873835) (Subject)

    8/30/23 4:15:02 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Immix Biopharma Inc. (Amendment)

    SC 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)

    3/2/22 2:57:11 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care